60 Degrees Pharmaceuticals Inc
SXTP4.160USD
+0.310+8.05%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
4.27MMarket Cap
3.70P/E TTM
More Details of 60 Degrees Pharmaceuticals Inc Company
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
60 Degrees Pharmaceuticals Inc Info
Ticker SymbolSXTP
Company name60 Degrees Pharmaceuticals Inc
IPO dateJul 12, 2023
CEODow (Geoffrey S)
Number of employees3
Security typeOrdinary Share
Fiscal year-endJul 12
Address1025 Connecticut Avenue Nw
CityWASHINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20036
Phone12023275422
Websitehttps://60degreespharma.com/
Ticker SymbolSXTP
IPO dateJul 12, 2023
CEODow (Geoffrey S)
Company Executives of 60 Degrees Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Geoffrey S. Dow, Ph.D.
Dr. Geoffrey S. Dow, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.36K
+5659.00%
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
3.95K
+1750.00%
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
1.32K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Commercial Officer
Chief Commercial Officer
1.14K
--
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
59.00
--
Dr. Stephen Toovey
Dr. Stephen Toovey
Independent Director
Independent Director
59.00
--
Mr. Paul Field
Mr. Paul Field
Independent Director
Independent Director
59.00
--
Mr. Patrick Gaynes
Mr. Patrick Gaynes
Investor Relations Officer
Investor Relations Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Geoffrey S. Dow, Ph.D.
Dr. Geoffrey S. Dow, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.36K
+5659.00%
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
3.95K
+1750.00%
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
1.32K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Commercial Officer
Chief Commercial Officer
1.14K
--
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
59.00
--
Dr. Stephen Toovey
Dr. Stephen Toovey
Independent Director
Independent Director
59.00
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Jan 21
Updated: Wed, Jan 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Orca Capital GmbH
3.23%
Dow (Geoffrey S)
0.88%
Knight Therapeutics, Inc.
0.66%
DRW Securities, LLC
0.49%
Xu (Cheryl)
0.31%
Other
94.43%
Shareholders
Shareholders
Proportion
Orca Capital GmbH
3.23%
Dow (Geoffrey S)
0.88%
Knight Therapeutics, Inc.
0.66%
DRW Securities, LLC
0.49%
Xu (Cheryl)
0.31%
Other
94.43%
Shareholder Types
Shareholders
Proportion
Investment Advisor
3.72%
Individual Investor
1.39%
Corporation
0.66%
Investment Advisor/Hedge Fund
0.24%
Hedge Fund
0.06%
Bank and Trust
0.03%
Other
93.89%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
25
52.23K
4.06%
-28.54K
2025Q3
22
451.55K
11.00%
+385.44K
2025Q2
28
103.95K
3.22%
+2.41K
2025Q1
28
93.99K
6.38%
-12.96K
2024Q4
26
104.62K
14.10%
+11.58K
2024Q3
25
101.03K
25.05%
+54.30K
2024Q2
23
54.29K
27.13%
-3.10K
2024Q1
19
57.35K
31.08%
+1.78K
2023Q4
19
60.17K
63.69%
+30.80K
2023Q3
18
63.13K
66.75%
+44.65K
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Orca Capital GmbH
166.23K
3.93%
+166.23K
--
Jul 16, 2025
Dow (Geoffrey S)
45.42K
1.07%
+22.63K
+99.30%
Dec 15, 2025
Knight Therapeutics, Inc.
33.90K
0.8%
+14.67K
+76.26%
Sep 30, 2024
DRW Securities, LLC
25.21K
0.6%
+25.21K
--
Sep 30, 2025
Xu (Cheryl)
15.82K
0.37%
+7.00K
+79.40%
Aug 26, 2025
Geode Capital Management, L.L.C.
12.45K
0.29%
-67.00
-0.54%
Sep 30, 2025
Miller (Tyrone)
5.27K
0.12%
--
--
Aug 26, 2025
Landon (Kristen)
4.54K
0.11%
--
--
Aug 26, 2025
Tower Research Capital LLC
3.14K
0.07%
+542.00
+20.86%
Sep 30, 2025
UBS Switzerland AG
1.48K
0.03%
+1.48K
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Jan 15, 2026
Merger
4→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Aug 06, 2024
Merger
12→1
Date
Ex-dividend Date
Type
Ratio
Jan 15, 2026
Merger
4→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1
